233 related articles for article (PubMed ID: 3162680)
1. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
Vega GL; East C; Grundy SM
Atherosclerosis; 1988 Mar; 70(1-2):131-43. PubMed ID: 3162680
[TBL] [Abstract][Full Text] [Related]
2. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
[TBL] [Abstract][Full Text] [Related]
3. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
[TBL] [Abstract][Full Text] [Related]
4. Plasma apolipoprotein B metabolism in familial type III dysbetalipoproteinaemia.
Turner PR; Cortese C; Wootton R; Marenah C; Miller NE; Lewis B
Eur J Clin Invest; 1985 Apr; 15(2):100-12. PubMed ID: 3922766
[TBL] [Abstract][Full Text] [Related]
5. Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia. Effects on kinetics of apolipoprotein B.
Vega GL; East C; Grundy SM
Arteriosclerosis; 1989; 9(1 Suppl):I135-44. PubMed ID: 2912427
[TBL] [Abstract][Full Text] [Related]
6. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
Vega GL; Grundy SM
Kidney Int; 1988 Jun; 33(6):1160-8. PubMed ID: 3165483
[TBL] [Abstract][Full Text] [Related]
8. Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
Bredie SJ; Westerveld HT; Knipscheer HC; de Bruin TW; Kastelein JJ; Stalenhoef AF
Neth J Med; 1996 Aug; 49(2):59-67. PubMed ID: 8824106
[TBL] [Abstract][Full Text] [Related]
9. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
Feussner G; Eichinger M; Ziegler R
Clin Investig; 1992 Nov; 70(11):1027-35. PubMed ID: 1472833
[TBL] [Abstract][Full Text] [Related]
10. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
Arad Y; Ramakrishnan R; Ginsberg HN
J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
[TBL] [Abstract][Full Text] [Related]
11. High receptor binding affinity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia).
Chappell DA
J Clin Invest; 1989 Dec; 84(6):1906-15. PubMed ID: 2556448
[TBL] [Abstract][Full Text] [Related]
12. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
[TBL] [Abstract][Full Text] [Related]
13. Influence of lovastatin on concentrations and composition of lipoprotein subfractions.
Nozaki S; Vega GL; Haddox RJ; Dolan ET; Grundy SM
Atherosclerosis; 1990 Oct; 84(2-3):101-10. PubMed ID: 2282090
[TBL] [Abstract][Full Text] [Related]
14. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia.
Kissebah AH; Alfarsi S; Adams PW
Metabolism; 1981 Sep; 30(9):856-68. PubMed ID: 7266376
[TBL] [Abstract][Full Text] [Related]
15. Regulation of low density lipoprotein apoprotein B metabolism by lovastatin and cholestyramine in miniature pigs: effects on LDL composition and synthesis of LDL subfractions.
Huff MW; Telford DE
Metabolism; 1989 Mar; 38(3):256-64. PubMed ID: 2918845
[TBL] [Abstract][Full Text] [Related]
16. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Frants RR; Havekes LM; Van der Laarse A; Van 't Hooft FM
Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss.
Ginsberg HN; Le NA; Gibson JC
J Clin Invest; 1985 Feb; 75(2):614-23. PubMed ID: 3973021
[TBL] [Abstract][Full Text] [Related]
18. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins.
Vega GL; Krauss RM; Grundy SM
J Intern Med; 1990 Feb; 227(2):81-94. PubMed ID: 2105373
[TBL] [Abstract][Full Text] [Related]
19. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.
Zambón D; Ros E; Rodriguez-Villar C; Laguna JC; Vázquez M; Sanllehy C; Casals E; Sol JM; Hernández G
Metabolism; 1999 Jan; 48(1):47-54. PubMed ID: 9920144
[TBL] [Abstract][Full Text] [Related]
20. Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia.
Tatò F; Keller C; Wolfram G
Clin Investig; 1993 Apr; 71(4):314-8. PubMed ID: 8471818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
